已收盤 06-18 16:00:00 美东时间
+0.330
+2.28%
今日重点评级关注:Ascendiant Capital:维持Outlook Therapeutics"买入"评级,目标价从6美元升至10美元;Ascendiant Capital:维持Aytu BioPharma"买入"评级,目标价从14美元升至14.5美元
06-12 11:32
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Rothschild & Co analyst Simon Clinch downgraded Marketaxess Holdings Inc (NASDAQ:MKTX) from Buy t...
06-11 23:42
William Blair analyst Dylan Carden downgrades J.Jill (NYSE:JILL) from Outperform to Market Perform.
06-11 23:22
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据J.Jill业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** 第一季度总销售额为1.44亿美元,同比下降6%,其中可比销售额下降8.7%。零售销售额下降约4%,直销渠道销售额下降约8%,直销占总销售额的46%。 **利润率表现:** 毛利率为68.3%,同比下降350个基点,主要受470万美元关税成本和更多降价销售影响。总毛利润约为9,870万美元,同比减少约1,200万美元。 **盈利能力:** 调整后EBITDA为1,670万美元,较去年同期的2,730万美元大幅下降。调整后每股摊薄净收益为0.45美元,低于去年
06-11 12:07
今日重点评级关注:Ascendiant Capital:维持NextTrip"买入"评级,目标价从7美元升至7.5美元;Maxim Group:维持Zevra Therapeutics"买入"评级,目标价从25美元升至35美元
06-11 09:55
BTIG analyst Janine Stichter reiterates J.Jill (NYSE:JILL) with a Buy and maintains $18 price target.
06-11 01:10
J.Jill (NYSE:JILL) reported first-quarter financial results on Wednesday. The transcript from the company's first-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/...
06-10 20:42
Companies Reporting Before The Bell • Chewy (NYSE:CHWY) is likely to report quarterly earnings at $0.39 per share on revenue of $3.35 billion. • J.Jill (NYSE:JILL) is likely to report quarterly earnings at $0.42 per share on revenue of $144.21 million. • Yuanbao (NASDAQ:YB) is estimated to report ea...
06-10 19:11
J.Jill (NYSE:JILL) widens FY2026 sales outlook from $584.618 million-$596.549 million to $584.618 million-$596.549 million vs $596.396 million estimate.
06-10 18:49
J.Jill (NYSE:JILL) sees Q2 sales of $149.367 million-$152.447 million vs $153.508 million analyst estimate.
06-10 18:47